このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Novacyt マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Lyn Rees

最高経営責任者

UK£336.1k

報酬総額

CEO給与比率	31.0%
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	less than a year
取締役会の平均在任期間	less than a year

経営陣の近況

Recent updates

CEO報酬分析

Novacyt の収益と比較して、Lyn Rees の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Dec 31 2023	UK£336k	UK£104k	-UK£28m

報酬と市場: Lynの総報酬 ($USD 426.52K ) は、 US市場 ($USD 674.46K ) の同様の規模の企業の平均を下回っています。

報酬と収益: Lynの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Lyn Rees (51 yo)

less than a year

在職期間

UK£336,106

報酬

Mr. Lyn Dafydd Rees serves as Executive Director at Novacyt S. A. since September 2023 and serves as its Chief Executive Officer since May 01, 2024. He serves as Non-Executive Director at MyHealthChecked P...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Lyn Rees	CEO & Executive Director	less than a year	UK£336.11k	データなし
Steve Gibson	CFO & Director	less than a year	データなし	データなし
Bryan Close	Chief Operations Officer	2.4yrs	データなし	データなし
Joanne Mason	Chief Scientific Officer & Director	less than a year	データなし	データなし
Mandy Cowling	Corporate & Investor Relations Manager	no data	データなし	データなし
David Franks	Chief Human Resources Officer	3.2yrs	データなし	データなし
Paul Oladimeji	Group Head of R&D	no data	データなし	データなし

0.4yrs

平均在職期間

経験豊富な経営陣: NVYT.Fの経営陣は経験豊富とはみなされません ( 0.4年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Lyn Rees	CEO & Executive Director	less than a year	UK£336.11k	データなし
Steve Gibson	CFO & Director	less than a year	データなし	データなし
Joanne Mason	Chief Scientific Officer & Director	less than a year	データなし	データなし
John Brown	Non-Executive Director	less than a year	UK£15.24k	データなし
Juliet Thompson	Independent Non-Executive Director	7yrs	UK£48.93k	データなし
Jean-Pierre Crinelli	Independent Non-Executive Director	no data	UK£34.04k	0.048% £ 20.3k
David Gardner	Member of Scientific Committee	no data	データなし	データなし
Marco Zonta	Member of Scientific Committee	no data	データなし	データなし
Isabelle Cartier	Member of Scientific Committee	no data	データなし	データなし
Geneviève Bourg-Heckly	Member of Scientific Committee	no data	データなし	データなし
James Wakefield	Independent Non-Executive Chairman of the Board	10.4yrs	UK£120.00k	0.062% £ 26.2k

0.8yrs

平均在職期間

54.5yo

平均年齢

経験豊富なボード: NVYT.Fの取締役会は経験豊富ではない ( 0.8年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Novacyt マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Novacyt S.A., Annual General Meeting, Jun 26, 2024

Novacyt S.A. Announces Changes to Its Board, Effective on May 1, 2024

Novacyt S.A., Annual General Meeting, Jun 15, 2023

Novacyt S.A. Announces Retirement of Non-Executive Director, Effective on 31 December 2022

Novacyt Announces Step Down of David Allmond as Member of the Board

Novacyt S.A., Annual General Meeting, Jun 21, 2022

Recent updates

Novacyt S.A., Annual General Meeting, Jun 26, 2024

Novacyt S.A. to Report Fiscal Year 2023 Results on May 30, 2024

Novacyt S.A. Notes DHSC Application for Summary Judgment Dismissed

Novacyt S.A. Announces Changes to Its Board, Effective on May 1, 2024

Novacyt S.A. to Report Q2, 2023 Results on Sep 28, 2023

Novacyt S.A. Provides Group Revenue Guidance for the First Half Ended June 30, 2023

Novacyt S.A., Annual General Meeting, Jun 15, 2023

Novacyt S.A. to Report Fiscal Year 2022 Results on Apr 24, 2023

Novacyt S.A. Announces Retirement of Non-Executive Director, Effective on 31 December 2022

Novacyt Announces Step Down of David Allmond as Member of the Board

Novacyt Announces Approval of genesig® SARS-CoV-2 Winterplex® 3 Gene Assay Panel in the UK Under CTDA Legislation

Novacyt S.A. Provides Group Financial Guidance for the Third Quarter and Year-To-Date Ended September 2022 and Fourth Quarter of 2022

Novacyt S.A. to Report First Half, 2022 Results on Sep 29, 2022

Novacyt Announces the Launch of the First Fully Lyophilised (Freeze-Dried), Direct-To-PCR Assays

Novacyt S.A. Launches Research-Use-Only Adenovirus F41 Assay

Novacyt S.A. Announces Approval of exsig COVID-19 Direct test in the UK

Novacyt Announces the Launch of Its Research-Use-Only Polymerase Chain Reaction Monkeypox Assay in Response to the Recent Outbreak of the Virus in Non-Endemic Countries

Novacyt S.A., Annual General Meeting, Jun 21, 2022

Novacyt S.A. Provides Update on DHSC Dispute

Novacyt Announces Approval of COVID-19 Test Under CTDA Legislation

Novacyt S.A. Announces Approval of the First Direct-To-PCR Covid-19 Test in the UK Under CTDA Legislation

Novacyt S.A. to Report Fiscal Year 2021 Results on Apr 25, 2022

Novacyt S.A. Reiterate Revenue Guidance for the Full Year

Novacyt S.A. Provides Sales Guidance for the Full Year 2021

Novacyt S.A. Announces the Launch of Two New Polymerase Chain Reaction Assays, Expanding its genesig® COVID-19 and SNPsig® SARS-CoV-2 Variant Detection Portfolios

Novacyt S.A. Announces Launch of VersaLab™ Portable

Novacyt S.A. Announces Inclusion of SNPsig SARS-CoV-2 PCR Genotyping Portfolio in the NHS England Framework and Expansion of SNPsig Product Range

Novacyt S.A. Provides Earnings Guidance for the Year 2021

Novacyt S.A. Announces Launch of PCR Genotyping Assay Portfolio to Detect Covid-19 Variants

Novacyt S.A. Announces Board Changes

Novacyt S.A. Appoints James McCarthy as Chief Financial Officer

Novacyt S.A. Announces the Development of Three Tests for New Strains of COVID-19 and Avian Influenza

Novacyt S.A. (ENXTPA:ALNOV) acquired IT-IS International Ltd. for £12 million.

Novacyt Signs a New Supply Contract with the UK Department of Health and Social Care

Novacyt S.A. Announces Launch of COVID-19 Antibody Test

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14